Effect	effect	O	O	O	O
of	of	O	O	O	O
nondopaminergic	nondopaminergic	O	O	O	O
drugs	drugs	O	O	O	O
on	on	O	O	O	O
L-dopa-induced	l-dopa-induced	O	O	O	O
dyskinesias	dyskinesias	O	DISEASE	OTHERS	I
in	in	O	O	O	O
MPTP-treated	mptp-treated	O	O	O	O
monkeys	monkeys	O	O	O	O
.	.	O	O	O	O

A	a	O	O	O	O
group	group	O	O	O	O
of	of	O	O	O	O
four	four	O	O	O	O
monkeys	monkeys	O	O	O	O
was	was	O	O	O	O
rendered	rendered	O	O	O	O
parkinsonian	parkinsonian	O	DISEASE	OTHERS	I
with	with	O	O	O	O
the	the	O	O	O	O
toxin	toxin	O	O	O	O
MPTP	mptp	CHEMICALS	O	OTHERS	I
.	.	O	O	O	O

They	they	O	O	O	O
were	were	O	O	O	O
then	then	O	O	O	O
treated	treated	O	O	O	O
chronically	chronically	O	O	O	O
with	with	O	O	O	O
L-DOPA/benserazide	l-dopa/benserazide	O	O	O	O
50/12.5	50/12.5	O	O	O	O
mg/kg	mg/kg	O	O	O	O
given	given	O	O	O	O
orally	orally	O	O	O	O
daily	daily	O	O	O	O
for	for	O	O	O	O
2	2	O	O	O	O
months	months	O	O	O	O
.	.	O	O	O	O

This	this	O	O	O	O
dose	dose	O	O	O	O
produced	produced	O	O	O	O
a	a	O	O	O	O
striking	striking	O	O	O	O
antiparkinsonian	antiparkinsonian	O	O	O	O
effect	effect	O	O	O	O
,	,	O	O	O	O
but	but	O	O	O	O
all	all	O	O	O	O
animals	animals	O	O	O	O
manifested	manifested	O	O	O	O
dyskinesia	dyskinesia	O	DISEASE	OTHERS	I
.	.	O	O	O	O

A	a	O	O	O	O
series	series	O	O	O	O
of	of	O	O	O	O
agents	agents	O	O	O	O
acting	acting	O	O	O	O
primarily	primarily	O	O	O	O
on	on	O	O	O	O
neurotransmitters	neurotransmitters	O	O	O	O
other	other	O	O	O	O
than	than	O	O	O	O
dopamine	dopamine	CHEMICALS	O	OTHERS	I
were	were	O	O	O	O
then	then	O	O	O	O
tested	tested	O	O	O	O
in	in	O	O	O	O
combination	combination	O	O	O	O
with	with	O	O	O	O
L-DOPA	l-dopa	O	O	O	O
to	to	O	O	O	O
see	see	O	O	O	O
if	if	O	O	O	O
the	the	O	O	O	O
dyskinetic	dyskinetic	O	O	OTHERS	I
movements	movements	O	O	OTHERS	I
would	would	O	O	O	O
be	be	O	O	O	O
modified	modified	O	O	O	O
.	.	O	O	O	O

Several	several	O	O	O	O
drugs	drugs	O	O	O	O
,	,	O	O	O	O
including	including	O	O	O	O
clonidine	clonidine	CHEMICALS	O	OTHERS	I
,	,	O	O	O	O
physostigmine	physostigmine	O	O	OTHERS	I
,	,	O	O	O	O
methysergide	methysergide	O	O	OTHERS	I
,	,	O	O	O	O
5-MDOT	5-mdot	O	O	OTHERS	I
,	,	O	O	O	O
propranolol	propranolol	CHEMICALS	O	OTHERS	I
,	,	O	O	O	O
and	and	O	O	O	O
MK-801	mk-801	CHEMICALS	O	OTHERS	I
,	,	O	O	O	O
markedly	markedly	O	O	O	O
reduced	reduced	O	O	O	O
the	the	O	O	O	O
dyskinetic	dyskinetic	O	O	OTHERS	I
movements	movements	O	O	OTHERS	I
but	but	O	O	O	O
at	at	O	O	O	O
the	the	O	O	O	O
cost	cost	O	O	O	O
of	of	O	O	O	O
a	a	O	O	O	O
return	return	O	O	O	O
of	of	O	O	O	O
parkinsonian	parkinsonian	O	DISEASE	OTHERS	I
symptomatology	symptomatology	O	O	O	O
.	.	O	O	O	O

However	however	O	O	O	O
,	,	O	O	O	O
yohimbine	yohimbine	CHEMICALS	O	OTHERS	I
and	and	O	O	O	O
meperidine	meperidine	O	O	OTHERS	I
reduced	reduced	O	O	O	O
predominantly	predominantly	O	O	O	O
the	the	O	O	O	O
dyskinetic	dyskinetic	O	O	OTHERS	I
movements	movements	O	O	OTHERS	I
.	.	O	O	O	O

Baclofen	baclofen	O	O	OTHERS	I
was	was	O	O	O	O
also	also	O	O	O	O
useful	useful	O	O	O	O
in	in	O	O	O	O
one	one	O	O	O	O
monkey	monkey	O	O	O	O
against	against	O	O	O	O
a	a	O	O	O	O
more	more	O	O	O	O
dystonic	dystonic	O	O	OTHERS	I
form	form	O	O	O	O
of	of	O	O	O	O
dyskinesia	dyskinesia	O	DISEASE	OTHERS	I
.	.	O	O	O	O

Atropine	atropine	CHEMICALS	O	OTHERS	I
converted	converted	O	O	O	O
the	the	O	O	O	O
dystonic	dystonic	O	O	OTHERS	I
movements	movements	O	O	O	O
into	into	O	O	O	O
chorea	chorea	O	O	OTHERS	I
.	.	O	O	O	O

